Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth H Fischbeck

Showing results (11-20 of 139) with videos related to

Pageof 14
Sort By:
Nature Neuroscience|June 16, 2021
Maybe too much of a good thing in gene therapyRichard S Finkel, Kenneth H Fischbeck
Lancet (London, England)|May 6, 2014
Nicotinamide in Friedreich's ataxia: useful or not?David R Lynch, Kenneth H Fischbeck
The New England Journal of Medicine|May 7, 2019
Oligonucleotide Treatment for Huntington's DiseaseKenneth H Fischbeck, Nancy S Wexler
Current Opinion in Genetics & Development|July 6, 2020
Nucleic acid therapeutics in neurodevelopmental diseaseAudrey M Winkelsas, Kenneth H Fischbeck
Annals of Neurology|March 5, 2009
Anti-androgen treatment for spinal and bulbar muscular atrophyKenneth H Fischbeck, Wilson W Bryan
Trends in Molecular Medicine|June 18, 2002
Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?J Paul Taylor, Kenneth H Fischbeck
Neurology|May 13, 2011
Amyotrophic lateral sclerosis and spinocerebellar ataxia 2Kenneth H Fischbeck, Stefan M Pulst
Nature Reviews. Genetics|October 6, 2005
Therapeutics development for triplet repeat expansion diseasesNicholas A Di Prospero, Kenneth H Fischbeck
Trends in Neurosciences|February 16, 2010
GARS axonopathy: not every neuron's cup of tRNAWilliam W Motley, Kevin Talbot, Kenneth H Fischbeck
Science (New York, N.Y.)|June 18, 2002
Toxic proteins in neurodegenerative diseaseJ Paul Taylor, John Hardy, Kenneth H Fischbeck
Pageof 14

Showing results (11-20 of 139) with videos related to

Sort By:
Pageof 14
Nature Neuroscience|June 16, 2021
Maybe too much of a good thing in gene therapyRichard S Finkel, Kenneth H Fischbeck
Lancet (London, England)|May 6, 2014
Nicotinamide in Friedreich's ataxia: useful or not?David R Lynch, Kenneth H Fischbeck
The New England Journal of Medicine|May 7, 2019
Oligonucleotide Treatment for Huntington's DiseaseKenneth H Fischbeck, Nancy S Wexler
Current Opinion in Genetics & Development|July 6, 2020
Nucleic acid therapeutics in neurodevelopmental diseaseAudrey M Winkelsas, Kenneth H Fischbeck
Annals of Neurology|March 5, 2009
Anti-androgen treatment for spinal and bulbar muscular atrophyKenneth H Fischbeck, Wilson W Bryan
Trends in Molecular Medicine|June 18, 2002
Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?J Paul Taylor, Kenneth H Fischbeck
Neurology|May 13, 2011
Amyotrophic lateral sclerosis and spinocerebellar ataxia 2Kenneth H Fischbeck, Stefan M Pulst
Nature Reviews. Genetics|October 6, 2005
Therapeutics development for triplet repeat expansion diseasesNicholas A Di Prospero, Kenneth H Fischbeck
Trends in Neurosciences|February 16, 2010
GARS axonopathy: not every neuron's cup of tRNAWilliam W Motley, Kevin Talbot, Kenneth H Fischbeck
Science (New York, N.Y.)|June 18, 2002
Toxic proteins in neurodegenerative diseaseJ Paul Taylor, John Hardy, Kenneth H Fischbeck
Pageof 14